Effect of olanzapine plus Rhus coriaria versus olanzapine plus placebo on the lipid profile of patients with bipolar disorder

Effect of olanzapine plus Rhus coriaria versus olanzapine plus placebo on the lipid profile of patients with bipolar disorder: a double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N541

Enrollment

Registered

2024-11-21

Start date

2024-12-21

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar disorder. Bipolar disorder

Interventions

Intervention 1: Intervention group: Elanzapine tablet 10 to 20 mg daily plus sumac capsule 500 mg daily for 6 weeks. Intervention 2: Control group: Elanzapine tablets 10 to 20 mg daily plus starch cap

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age of 18 to 65 years Bipolar disorder

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Taking lipid-lowering drugs

Design outcomes

Primary

Measure	Time frame
Serum levels of lipid profiles (triglycerides, cholesterol, LDL, HDL). Timepoint: Before the intervention and 12 weeks later. Method of measurement: By taking blood sample.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHosein Jafari

Hamedan University of Medical Sciences

ariyanjafari900@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026